Kala Bio Inc (NAS:KALA)

$ 6.89 -0.045 (-0.65%) Market Cap: 31.97 Mil Enterprise Value: 16.60 Mil PE Ratio: 0 PB Ratio: 4.68 GF Score: 44/100

KALA BIO Inc at HC Wainwright Ophthalmology Virtual Conference - Pre Recorded Transcript
Aug 16, 2023
Kala Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q2 2022 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

$16.4 (-5.75%)

Earnings
Q1 2022 Kala Pharmaceuticals Inc Earnings Call Transcript
May 16, 2022

$37.08 (+8.47%)

Earnings
Q4 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Mar 29, 2022

$75 (-14.29%)

Earnings
Q3 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 15, 2021

$105 (+1.45%)

Earnings
Q2 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 05, 2021

$159 (-5.07%)

Earnings
Kala Pharmaceuticals Inc at BofA Securities 2021 Healthcare Conference (Virtual) Transcript
May 13, 2021
Q1 2021 Kala Pharmaceuticals Inc Earnings Call Transcript
May 05, 2021

$297.5 (-7.75%)

Earnings
Q4 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Feb 25, 2021

$386.75 (-13.38%)

Earnings
Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 05, 2020

$363 (+0.14%)

Earnings
Kala Pharmaceuticals, Inc. - Special Call Transcript
Oct 27, 2020
Kala Pharmaceuticals, Inc. - Special Call Transcript
Sep 17, 2020
Q2 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2020

$458.5

Earnings
Kala Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Q1 2020 Kala Pharmaceuticals Inc Earnings Call Transcript
May 07, 2020

$592.5 (+1.98%)

Earnings
Kala Pharmaceuticals Inc STRIDE 3 Data Conference Call Transcript
Mar 09, 2020
Q4 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Feb 12, 2020

$313.5 (-1.95%)

Earnings
Kala Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Nov 07, 2019

$185.5 (-3.39%)

Earnings
Q2 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2019

$219 (-13.27%)

Earnings
Kala Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 14, 2019
Q1 2019 Kala Pharmaceuticals Inc Earnings Call Transcript
May 09, 2019

$347 (-2.25%)

Earnings
Q4 2018 Kala Pharmaceuticals Inc Earnings Call Transcript
Mar 11, 2019

Earnings

Kala Pharmaceuticals, Inc. - Special Call Transcript

Sep 17, 2020 / 12:00PM GMT

Release Date Price: $437 (+1.51%)

Transcript

Operator

Good morning and welcome to the Kala Pharmaceuticals investor and analyst event. (Operator Instructions) I would now like to turn the call over to Niranjan Kameswaran, Senior Vice President of Strategy for Kala Pharmaceuticals. Please proceed.

Niranjan Kameswaran

Kala Pharmaceuticals, Inc. - SVP of Strategy

Thank you, operator, and thank you, everyone, for joining us today. Today's event will focus on EYSUVIS, our product candidate for the short-term treatment of dry eye disease and is being webcast live. The audio webcast link along with the slides for today's presentation can be found in the Events page on the Investors section of our website, Kalarx.com. Please open the slides now. We kindly ask that you manually advance the slides as the speakers move through the presentation.

On this call, we will make certain comments about Kala's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements will include information regarding the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.